Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review

@article{Diel2008RiskOR,
  title={Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review},
  author={Ingo Jakob Diel and Rudolf Weide and Hubert Koeppler and Lucia Antr{\`a}s and Michael Smith and Jesse Green and Neil Wintfeld and Maureen P. Neary and Mei Sheng Duh},
  journal={Supportive Care in Cancer},
  year={2008},
  volume={17},
  pages={719-725}
}
This retrospective study compared renal impairment rates in breast cancer, multiple myeloma, prostate cancer and non-small cell lung cancer patients treated with ibandronate or zoledronic acid. Medical records in two German oncology clinics from May 2001 to March 2006 were retrospectively reviewed. Creatinine measurements were analyzed from baseline (before bisphosphonate treatment) to last available measurement for each patient. The Cox proportional hazards model and the Andersen–Gill… CONTINUE READING
18 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study

  • R Eastell, P Garnero, B Vrijens
  • Calcif Tissue Int
  • 2006
1 Excerpt

Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data [abstract 68

  • JJ Body, M Lichinitser, S Tjulandin, B Bergström
  • 2006
1 Excerpt

Renal impairment in cancer patients following zoledronic acid or ibandronate treatment [abstract 1002P

  • IJ Diel, R Weide, H Köppler
  • Ann Oncol
  • 2006
2 Excerpts

Renal safety of intravenous ibandronate 6 mg infused over 15 minutes or 60 minutes in patients with breast cancer and bone metastases [ abstract 1078

  • R vonMoos, CB Caspar, R Angst
  • Support Care Cancer
  • 2006

Renal safety of intravenous ibandronate 6 mg infused over 15 minutes or 60 minutes in patients with breast cancer and bone metastases [abstract

  • R von Moos, CB Caspar, R Angst
  • Support Care Cancer
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…